Locations
North Carolina, USA · Raleigh, NC, USA
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Series A
founded in
2014
Aer Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for muco-obstructive lung diseases, particularly targeting conditions like COPD, cystic fibrosis, and asthma. Their lead product, AER-01, is a novel inhaled mucolytic agent designed to effectively liquefy mucus plugs, addressing a significant unmet medical need in patients suffering from airway obstruction. The company leverages advanced lung imaging techniques to identify patients with clinically silent mucus plugs and measure the efficacy of their treatments. With a strong foundation in research and development, supported by over $18M in NIH funding, Aer Therapeutics is positioned to make a substantial impact in the respiratory disease market.
Something looks off?